{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:47:15Z","timestamp":1792586835786,"version":"4.5.0"},"reference-count":43,"publisher":"MyJove Corporation","issue":"232","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/71315","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:01:57Z","timestamp":1782255717000},"source":"Crossref","is-referenced-by-count":0,"title":["Bleeding Risk Associated with Novel Oral Anticoagulants in Critically Ill Patients: A Scoping Review"],"prefix":"10.3791","author":[{"given":"Zhichao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","type":"journal-article","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","unstructured":"Connolly, S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England journal of medicine. 361 (12), 1139-1151 (2009).","journal-title":"New England journal of medicine"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","type":"journal-article","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","unstructured":"Patel, M.R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 365 (10), 883-891 (2011).","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","type":"journal-article","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","unstructured":"Granger, C.B. et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 365 (11), 981-992 (2011).","journal-title":"New England Journal of Medicine"},{"issue":"9921","key":"ref4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","type":"journal-article","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","unstructured":"Ruff, C.T. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 383 (9921), 955-962 (2014).","journal-title":"The Lancet"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrneph.2011.92","type":"journal-article","article-title":"Implications of augmented renal clearance in critically ill patients","volume":"7","author":"Udy","year":"2011","unstructured":"Udy, A.A., Roberts, J.A., Lipman, J. Implications of augmented renal clearance in critically ill patients. Nature Reviews Nephrology. 7 (9), 539-543 (2011).","journal-title":"Nature Reviews Nephrology"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13613-017-0341-y","type":"journal-article","article-title":"Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies","volume":"7","author":"Russell","year":"2017","unstructured":"Russell, L., Holst, L.B., Kjeldsen, L., Stensballe, J., Perner, A. Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies. Annals of Intensive Care. 7 (1), 119 (2017).","journal-title":"Annals of Intensive Care"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00134-013-3044-3","type":"journal-article","article-title":"Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis","volume":"39","author":"Lauzier","year":"2013","unstructured":"Lauzier, F. et al. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive care medicine. 39 (12), 2135-2143 (2013).","journal-title":"Intensive care medicine"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","type":"journal-article","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","unstructured":"Roberts, J.A. et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. The Lancet infectious diseases. 14 (6), 498-509 (2014).","journal-title":"The Lancet infectious diseases"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.51893\/2021.1.OA9","type":"journal-article","article-title":"A fixed dose approach to thrombosis chemoprophylaxis may be inadequate in heavier critically ill patients","volume":"23","author":"Yi","year":"2021","unstructured":"Yi, G., Deane, A.M., Ankravs, M., Sharrock, L., Anstey, J., Abdelhamid, Y.A. A fixed dose approach to thrombosis chemoprophylaxis may be inadequate in heavier critically ill patients. Critical Care and Resuscitation. 23 (1), 94-102 (2021).","journal-title":"Critical Care and Resuscitation"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ehjcvp\/pvaa135","type":"journal-article","article-title":"Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI","volume":"8","author":"Costa","year":"2022","unstructured":"Costa, F. et al. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. European Heart Journal-Cardiovascular Pharmacotherapy. 8 (3), 216-226 (2022).","journal-title":"European Heart Journal-Cardiovascular Pharmacotherapy"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","type":"journal-article","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","unstructured":"Arksey, H., O\u2019malley, L. Scoping studies: towards a methodological framework. International journal of social research methodology. 8 (1), 19-32 (2005).","journal-title":"International journal of social research methodology"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1748-5908-5-69","type":"journal-article","article-title":"Scoping studies: advancing the methodology","volume":"5","author":"Levac","year":"2010","unstructured":"Levac, D., Colquhoun, H., O\u2019brien, K.K. Scoping studies: advancing the methodology. Implementation science. 5 (1), 69 (2010).","journal-title":"Implementation science"},{"key":"ref13","type":"book","article-title":"10. Scoping reviews","volume-title":"JBI manual for evidence synthesis","author":"Peters","year":"2020","unstructured":"Peters, M.D.J., Godfrey, C., McInerney, P., Munn, Z., Tricco, A.C., Khalil, H. 10. Scoping reviews. JBI manual for evidence synthesis. (2020)."},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","type":"journal-article","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","unstructured":"Tricco, A.C. et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Annals of internal medicine. 169 (7), 467-473 (2018).","journal-title":"Annals of internal medicine"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","type":"journal-article","article-title":"Anticoagulation strategies in patients with cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","unstructured":"Mosarla, R.C., Vaduganathan, M., Qamar, A., Moslehi, J., Piazza, G., Giugliano, R.P. Anticoagulation strategies in patients with cancer: JACC review topic of the week. Journal of the American College of Cardiology. 73 (11), 1336-1349 (2019).","journal-title":"Journal of the American College of Cardiology"},{"issue":"27","key":"ref16","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/eurheartj\/ehw058","type":"journal-article","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"38","author":"Heidbuchel","year":"2017","unstructured":"Heidbuchel, H. et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. European heart journal. 38 (27), 2137-2149 (2017).","journal-title":"European heart journal"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1055\/s-0040-1710326","type":"journal-article","article-title":"Prevention of venous thromboembolism in hospitalized medically ill patients: a US perspective","volume":"120","author":"Spyropoulos","year":"2020","unstructured":"Spyropoulos, A.C., Ageno, W., Cohen, A.T., Gibson, C.M., Goldhaber, S.Z., Raskob, G. Prevention of venous thromboembolism in hospitalized medically ill patients: a US perspective. Thrombosis and Haemostasis. 120 (06), 924-936 (2020).","journal-title":"Thrombosis and Haemostasis"},{"issue":"22","key":"ref18","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.3390\/jcm10225369","type":"journal-article","article-title":"Coagulopathies in intensive care medicine: balancing act between thrombosis and bleeding","volume":"10","author":"Neuenfeldt","year":"2021","unstructured":"Neuenfeldt, F.S., Weigand, M.A., Fischer, D. Coagulopathies in intensive care medicine: balancing act between thrombosis and bleeding. Journal of clinical medicine. 10 (22), 5369 (2021).","journal-title":"Journal of clinical medicine"},{"issue":"8","key":"ref19","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","type":"journal-article","article-title":"Drug\u2013drug interactions with direct oral anticoagulants","volume":"59","author":"Foerster","year":"2020","unstructured":"Foerster, K.I., Hermann, S., Mikus, G., Haefeli, W.E. Drug\u2013drug interactions with direct oral anticoagulants. Clinical pharmacokinetics. 59 (8), 967-980 (2020).","journal-title":"Clinical pharmacokinetics"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","type":"journal-article","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama. 315 (8), 801-810 (2016).","journal-title":"Jama"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/SHK.0000000000000473","type":"journal-article","article-title":"The endothelium in sepsis","volume":"45","author":"Ince","year":"2016","unstructured":"Ince, C. et al. The endothelium in sepsis. Shock. 45 (3), 259-270 (2016).","journal-title":"Shock"},{"issue":"19","key":"ref22","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","type":"journal-article","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"Qamar","year":"2018","unstructured":"Qamar, A., Vaduganathan, M., Greenberger, N.J., Giugliano, R.P. Oral anticoagulation in patients with liver disease. Journal of the American College of Cardiology. 71 (19), 2162-2175 (2018).","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40256-023-00582-9","type":"journal-article","article-title":"Management of gastrointestinal bleeding and resumption of oral anticoagulant therapy in patients with atrial fibrillation: a multidisciplinary discussion","volume":"23","author":"Martin","year":"2023","unstructured":"Martin, A.-C., Benamouzig, R., Gouin-Thibault, I., Schmidt, J. Management of gastrointestinal bleeding and resumption of oral anticoagulant therapy in patients with atrial fibrillation: a multidisciplinary discussion. American Journal of Cardiovascular Drugs. 23 (4), 407-418 (2023).","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-025-00719-7","type":"journal-article","article-title":"Cancer-associated venous thromboembolism: a comprehensive review","volume":"23","author":"Wan","year":"2025","unstructured":"Wan, T., Song, J., Zhu, D. Cancer-associated venous thromboembolism: a comprehensive review. Thrombosis Journal. 23 (1), 35 (2025).","journal-title":"Thrombosis Journal"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1097\/CCM.0000000000006330","type":"journal-article","article-title":"Society of Critical Care Medicine and American Society of Health-System Pharmacists guideline for the prevention of stress-related gastrointestinal bleeding in critically ill adults","volume":"52","author":"MacLaren","year":"2024","unstructured":"MacLaren, R. et al. Society of Critical Care Medicine and American Society of Health-System Pharmacists guideline for the prevention of stress-related gastrointestinal bleeding in critically ill adults. Critical Care Medicine. 52 (8), e421-e430 (2024).","journal-title":"Critical Care Medicine"},{"issue":"1_suppl","key":"ref26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/23969873231222393","type":"journal-article","article-title":"Principles of reversal of anticoagulation in patients with intracerebral hemorrhage related to oral anticoagulants","volume":"10","author":"Christensen","year":"2025","unstructured":"Christensen, H. et al. Principles of reversal of anticoagulation in patients with intracerebral hemorrhage related to oral anticoagulants. European Stroke Journal. 10 (1_suppl), 4-13 (2025).","journal-title":"European Stroke Journal"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.chest.2016.01.023","type":"journal-article","article-title":"Risk of procedural hemorrhage","volume":"150","author":"Wolfe","year":"2016","unstructured":"Wolfe, K.S., Kress, J.P. Risk of procedural hemorrhage. Chest. 150 (1), 237-246 (2016).","journal-title":"Chest"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/clc.22037","type":"journal-article","article-title":"Emergency management of bleeding associated with old and new oral anticoagulants","volume":"35","author":"Frank Peacock","year":"2012","unstructured":"Frank Peacock, W., Gearhart, M.M., Mills, R.M. Emergency management of bleeding associated with old and new oral anticoagulants. Clinical Cardiology. 35 (12), 730-737 (2012).","journal-title":"Clinical Cardiology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"10742484231202656","DOI":"10.1177\/10742484231202655","type":"journal-article","article-title":"Evidence-based Management of Major Bleeding in patients receiving direct oral anticoagulants: an updated narrative review on the role of specific reversal agents","volume":"28","author":"Al Aseri","year":"2023","unstructured":"Al Aseri, Z., AlGahtani, F.H., Bakheet, M.F., Al-Jedai, A.H., Almubrik, S. Evidence-based Management of Major Bleeding in patients receiving direct oral anticoagulants: an updated narrative review on the role of specific reversal agents. Journal of Cardiovascular Pharmacology and Therapeutics. 28, 10742484231202656 (2023).","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/13696998.2016.1273229","type":"journal-article","article-title":"Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD TM study","volume":"20","author":"Pollack","year":"2017","unstructured":"Pollack Jr, C. V et al. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADTM study. Journal of Medical Economics. 20 (5), 435-442 (2017).","journal-title":"Journal of Medical Economics"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","type":"journal-article","article-title":"Pharmacokinetic alterations associated with critical illness","volume":"62","author":"Morales Castro","year":"2023","unstructured":"Morales Castro, D., Dresser, L., Granton, J., Fan, E. Pharmacokinetic alterations associated with critical illness. Clinical Pharmacokinetics. 62 (2), 209-220 (2023).","journal-title":"Clinical Pharmacokinetics"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3904\/kjim.2014.152","type":"journal-article","article-title":"Bleeding complications in critically ill patients with liver cirrhosis","volume":"31","author":"Cho","year":"2016","unstructured":"Cho, J. et al. Bleeding complications in critically ill patients with liver cirrhosis. The Korean journal of internal medicine. 31 (2), 288 (2016).","journal-title":"The Korean journal of internal medicine"},{"issue":"8","key":"ref33","first-page":"845","type":"journal-article","article-title":"How I treat disseminated intravascular coagulation","volume":"131","author":"Levi","year":"2018","unstructured":"Levi, M., Scully, M. How I treat disseminated intravascular coagulation. Blood, The Journal of the American Society of Hematology. 131 (8), 845-854 (2018).","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","type":"journal-article","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","unstructured":"Connolly, S.J. et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. New England Journal of Medicine. 375 (12), 1131-1141 (2016).","journal-title":"New England Journal of Medicine"},{"key":"ref35","type":"book","article-title":"Anticoagulation safety","volume-title":"StatPearls","author":"Amaraneni","year":"2024","unstructured":"Amaraneni, A., Chippa, V., Goldin, J., Rettew, A.C. Anticoagulation safety. StatPearls [Internet]. (2024)."},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0034-1398376","type":"journal-article","article-title":"Coagulation in patients with severe sepsis","volume":"41","author":"Levi","year":"2015","unstructured":"Levi, M., van der Poll, T. Coagulation in patients with severe sepsis. Seminars in thrombosis and hemostasis. 41 (01), 9-15 (2015).","journal-title":"Seminars in thrombosis and hemostasis"},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/jth.14975","type":"journal-article","article-title":"Coagulopathy in COVID-19","volume":"18","author":"Iba","year":"2020","unstructured":"Iba, T., Levy, J.H., Levi, M., Thachil, J. Coagulopathy in COVID-19. Journal of thrombosis and haemostasis. 18 (9), 2103-2109 (2020).","journal-title":"Journal of thrombosis and haemostasis"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","type":"journal-article","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","unstructured":"Pisters, R., Lane, D.A., Nieuwlaat, R., De Vos, C.B., Crijns, H.J.G.M., Lip, G.Y.H. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 138 (5), 1093-1100 (2010).","journal-title":"Chest"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"574-e13","DOI":"10.1016\/j.amjmed.2017.11.046","type":"journal-article","article-title":"The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants","volume":"131","author":"Lip","year":"2018","unstructured":"Lip, G.Y.H., Skj\u00f8th, F., Nielsen, P.B., Kj\u00e6ldgaard, J.N., Larsen, T.B. The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants. The American journal of medicine. 131 (5), 574-e13 (2018).","journal-title":"The American journal of medicine"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0049-3848(14)50006-0","type":"journal-article","article-title":"Risk stratification strategies for cancer-associated thrombosis: an update","volume":"133","author":"Khorana","year":"2014","unstructured":"Khorana, A.A., McCrae, K.R. Risk stratification strategies for cancer-associated thrombosis: an update. Thrombosis research. 133, S35-S38 (2014).","journal-title":"Thrombosis research"},{"issue":"14","key":"ref41","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","type":"journal-article","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","unstructured":"Connolly, S.J. et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. New England Journal of Medicine. 380 (14), 1326-1335 (2019).","journal-title":"New England Journal of Medicine"},{"key":"ref42","doi-asserted-by":"crossref","DOI":"10.1002\/9781119237662.ch4","type":"book","article-title":"Coagulation in Cirrhosis","volume-title":"Sherlock\u2019s Diseases of the Liver and Biliary System","author":"Intagliata","year":"2018","unstructured":"Intagliata, N.M., Caldwell, S.H. Coagulation in Cirrhosis. Sherlock\u2019s Diseases of the Liver and Biliary System. 53-61 (2018)."},{"issue":"05","key":"ref43","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1055\/s-0035-1550440","type":"journal-article","article-title":"Liver disease and hemostatic (dys) function","volume":"41","author":"Tripodi","year":"2015","unstructured":"Tripodi, A. Liver disease and hemostatic (dys) function. Seminars in thrombosis and hemostasis. 41 (05), 462-467 (2015).","journal-title":"Seminars in thrombosis and hemostasis"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/71315\/bleeding-risk-associated-with-novel-oral-anticoagulants-critically","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:26:34Z","timestamp":1792585594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/71315\/bleeding-risk-associated-with-novel-oral-anticoagulants-critically"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":43,"journal-issue":{"issue":"232","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/71315","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}